Endometriosis affects 1 in 10 women worldwide with debilitating pain. There are currently no good treatment options that are fertility-friendly and disease-modifying.
Endometriosis has no cure and current therapies are inadequate for most patients.
Hysterectomy or repeat laparoscopy. High cost, risk of sterilization, and pain often returns.
Chronic use carries high risk of dependency, tolerance, and severe side effects with limited long-term benefit.
Severe bone mineral density loss. Limited to 24 months of use. High cost and significant side effects.
Ineffective for many. Suppresses symptoms without addressing underlying disease. Not fertility-friendly.
1 in 10 women of reproductive age suffer from endometriosis with no effective, fertility-preserving therapy available today.
Our lead investigational asset leverages a well-characterized small molecule with decades of established safety data — reformulated for endometriosis with proprietary composition-of-matter IP.
Normalization of multiple dysregulated inflammatory cascades, including IL-1β, TNF-α, IL-6, IL-17, and NF-κB that drive endometriosis pathology, without suppressing the regular functioning of these pathways to prevent infection.
Refluxed menses escaping into the peritoneum utilize dysregulated autophagy to survive, implant, and create endometriotic lesions. Normalization of autophagy inhibits this pathology.
Designed to go beyond symptom suppression by addressing drivers of lesion-associated pain and progression.
An established safety profile from decades of use in other indications.
Proprietary SLBST formulation designed to simplify compliance and improve long-term safety.
Issued method-of-use patents. Pending composition-of-matter IP.
By addressing key drivers of endometriosis rather than masking symptoms, our investigational program offers the possibility of meaningful, lasting relief — while preserving fertility and long-term health.
Independent preclinical and observational findings provide the foundation for our approach in endometriosis. Full datasets available in the data room for qualified investors.
In established models, the approach produced 60% fewer lesions. Half of treated subjects developed no lesions at all.
| Attribute | SLBST Program | Surgery | Opioids | GnRH | Hormonal BC |
|---|---|---|---|---|---|
| Annual Cost (US) | Cost Effective | ~$20K per procedure | Variable / high | $10–15K/yr | <$1K/yr |
| Fertility Impact | Fertility friendly | Sterilization risk | None direct | Contraindicated | Blocks / delays |
| Safety Profile | Decades of data | Surgical risks | Addiction risk | Bone loss (24mo limit) | Systemic effects |
| Disease Modification | Yes — targets underlying drivers | Temporary | None | Temporary | None |
| Development Status | Phase 2b-ready 505(b)(2) pathway | Commercial | Commercial | Commercial | Commercial |
Deep expertise across drug development, commercialization, gynecology, and endometriosis research.
Twice exited founder. Relaunched OPV Pharmaceutical Holdings in Vietnam. Founded Nu Science Labs and nuBound.
Former Therapeutic Area Head at Novartis for Infectious & Autoimmune Diseases. Extensive preclinical leadership.
Former Senior Med Director, Bayer. Founding Branch Chief NICHD/NIH Gynecologic Health & Disease. Former Professor, UT Southwestern.
REI Specialist at Pinnacle Fertility. Fellow at Yale. Published extensively on the immunological basis of endometriosis.
Founder of LBRIA clinical services. Led clinical trial & regulatory approval for relugolix (GnRH antagonist) on behalf of Myovant.
We are advancing a de-risked, IP-protected asset with a clear path to approval in a massive, underserved market.